BAYRY's 2025 Revival: Will the Momentum Continue in 2026?

Key Takeaways Bayer stock surged 121.6% in a year, far outpacing the industry, sector and the S&P 500.BAYRY is boosted by FDA label expansions for Nubeqa and Kerendia, plus approvals for Lynkuet and Hyrnuo.Bayer also gained from a favorable U.S. Supreme Court review signal in Roundup litigation.2025 has proved to be a turnaround for the German pharmaceutical giant Bayer (BAYRY) . Shares have skyrocketed 121.6% over the past year compared with the industry’s gain of 19.2%.  The stock has also outperformed t ...